CMS Entry id: 2709 | Channel: Blog landing page | Template: blog/index

Login
Facebook YouTube Twitter Linkedin
Facebook YouTube Twitter Linkedin

Blog

Evolocumab Phase 3 Cognitive Function Study Results Published in the New England Journal of Medicine

Cambridge Cognition and Amgen announce that the New England Journal of Medicine (NEJM) published results from the evolocumab cognitive function trial, which was conducted in a subset of patients enrolled in the randomized, placebo-controlled evolocumab cardiovascular outcomes study.

CANTAB assessments used in EBBINGHAUS cognitive function trial for Amgen's evolocumab

Cambridge Cognition today reports its involvement in Amgen's EBBINGHAUS study with full results being presented at the American College of Cardiology Annual Scientific Session on 18 March 2017.

Design and rationale of the EBBINGHAUS trial

The Journal Clinical Cardiology has published on the design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo controlled, multicenter study to assess the effect of the human anti-PCSK9 monoclonal antibody evolocumab on cognitive function in patients with clinically evident cardiovascular disease receiving statin background lipid-lowering therapy1.

web-based testing, wearables, voice, virtual clinical trials, technology, swm, subjective measures, stigma, social cognition, smartphones, sleep, schizophrenia research, schizophrenia, safety, rvp, rti, research funding, research, remote testing, regulations, recruitment, rare disease, prodromal, pro-cognitive, prm, press release, presenteeism, precision psychiatry, pre-clinical, poster, personalised medicine, patient-centric, patient recruitment, parkinson's disease, pal, paired associates learning, ots, occupational health, normative data, neuroscience, near-patient testing, multiple sclerosis, mts, ms, modelling, mental wellbeing, mdd, mci, major depression, machine learning, life at cambridge cognition, high-frequency testing, healthcare, grant, funding, fatigue, ert, epidemiology, ebt, early career researchers, early alzheimer's disease, drug development, dms, digital tools, digital health, depression, dementia, covid-19, cognitive testing, cognitive science, cognitive safety, cognitive impairment, cognitive function, cognitive dysfunction, cognitive deficits, cognitive biomarkers, cognitive assessment, cognition kit, cognition, cns summit, clinical trials, clinical trial, cias, chronic illness, chronic health conditions, cgt, cantab testimonial, cantab research grant, cantab, cambridge cognition careers, cambridge cognition, brain health, biomarkers, automatic speech recognition, autism, attention, asr, alzheimer's disease, academic, absenteeism,